
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Meda will acquire Acton Pharmaceuticals.
The specialty pharmaceutical company,
The launch of Aerospan is expected to begin in 2014 for $135 million plus $10 million in a contingent, near-term development milestone. Acton will also receive certain sales-based milestones, which may bring the total potential acquisition value of up to $200 million.
Source:






